| __timestamp | MorphoSys AG | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9689000 | 17986000 |
| Thursday, January 1, 2015 | 10431000 | 32480000 |
| Friday, January 1, 2016 | 9618000 | 68081000 |
| Sunday, January 1, 2017 | 12348000 | 169906000 |
| Monday, January 1, 2018 | 28310241 | 248932000 |
| Tuesday, January 1, 2019 | 59336147 | 354100000 |
| Wednesday, January 1, 2020 | 159145941 | 433300000 |
| Friday, January 1, 2021 | 199800000 | 583300000 |
| Saturday, January 1, 2022 | 90225000 | 752700000 |
| Sunday, January 1, 2023 | 92538000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Cracking the code
In the competitive world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and MorphoSys AG from 2014 to 2023. Over this period, Neurocrine Biosciences has consistently outpaced MorphoSys AG, with its SG&A expenses growing by nearly 500%, reaching a peak in 2023. In contrast, MorphoSys AG's expenses increased by approximately 850%, albeit from a smaller base, indicating a more aggressive expansion strategy. Notably, Neurocrine's expenses in 2023 were almost 10 times higher than in 2014, reflecting its significant market presence. Meanwhile, MorphoSys AG's expenses surged in 2020, suggesting strategic investments during the pandemic. These trends highlight the differing growth trajectories and strategic priorities of these two biotech leaders, offering valuable insights for investors and industry analysts alike.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MorphoSys AG
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
MorphoSys AG and Evotec SE: SG&A Spending Patterns Compared